Litcius/Paper detail

Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial

Chantal Mathieu, Francesco Giorgino, Sin Gon Kim, J. S. Larsen, Athena Philis‐Tsimikas, Ambady Ramachandran, Thaís Rocha, Vinay Babu Shankarappa, Yasuo Terauchi, Linong Ji

2025The Lancet Diabetes & Endocrinology18 citationsDOI

Topics & Concepts

MedicineOpen labelType 2 diabetesInsulinRandomized controlled trialDiabetes mellitusInternal medicineMEDLINEEndocrinologyPolitical scienceLawDiabetes Treatment and ManagementDiabetes and associated disordersGastrointestinal motility and disorders
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial | Litcius